Increased hypoxia |
Increases HIF1-a and PD-L1 on MDSCs for T cell exhaustion and Treg generation |
Anti-PD-L1 and HIF inhibitors |
[43,69,70] |
Increased reactive oxygen species |
Oxidative stress-mediated inhibition of NF-kB or mTOR for the prevention of T cell activation |
Catalase, an antioxidant enzyme |
[32,42] |
Decreased glucose availability |
Reduced AKT, mTOR, GLUT1, phosphoenolpyruvate, and increased PD-1 expression in T cells |
anti-PD-1, anti-PD-L1, anti-CTLA-4 |
[27,46,48,49,50] |
Increased lactate |
Inhibition of T cell glycolysis and function |
Blocking acidification prior to anti-PD-1 or anti-CTLA-4 administration |
[52] |
Low levels of arginine |
Reduced responsiveness of T cells due to decreased expression of CD3ζ chain |
Administering arginine |
[55,56] |